Riderflex

Mark Bagnall is a distinguished leader in the healthcare and biotech industries, currently at the helm of Phenomix Sciences, Inc. as CEO. With a rich background that includes roles as CEO, COO, and CFO, Mark has co-founded three startups in the past six years, and his strategic vision has guided several companies through successful M&A transactions, raising over $500 million in the process. Before Phenomix, he was an Executive-in-Residence at Health2047, identifying new business opportunities and played a key role in the acquisition of Naia Rare Diseases by 9 Meters Biopharma. A CPA by training, Mark's career began at Ernst & Young, and he has since become known for his ability to navigate the complex biotech landscape, making significant contributions as an executive, board member, and investor. Phenomix Sciences is at the forefront of combating the obesity epidemic through precision medicine, leveraging groundbreaking technology rooted in Mayo Clinic's hard science. With obesity rates doubli